Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jan;65(1):90–95. doi: 10.1038/bjc.1992.17

Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.

M B Parliament 1, J D Chapman 1, R C Urtasun 1, A J McEwan 1, L Golberg 1, J R Mercer 1, R H Mannan 1, L I Wiebe 1
PMCID: PMC1977349  PMID: 1310253

Abstract

Non-invasive predictive assays which can confirm the presence or absence of hypoxic cells in human tumours show promise for understanding the natural history of tumour oxygenation, and improving the selection of patient subsets for novel radiotherapeutic strategies. Sensitiser adducts have been proposed as markers for hypoxic cells. Misonidazole analogues radiolabelled with iodine-123 have been developed for the detection of tumour hypoxia using conventional nuclear medicine techniques. In this pilot study, we have investigated one such potential marker, 123I-iodoazomycin arabinoside (123I-IAZA). Patients with advanced malignancies have undergone planar and single-photon emission computed tomographic (SPECT) imaging after intravenous administration of 123I-IAZA. We have observed radiotracer avidity in three out of ten tumours studied to date. Normal tissue activity of variable extent was also seen in the thyroid and salivary glands, upper aerodigestive tract, liver, intestine, and urinary bladder. Quantitative analysis of those images showing radiotracer avidity revealed tumour/normal tissue (T/N) ratios of 2.3 (primary small cell lung carcinoma), 1.9 (primary malignant fibrous histiocytoma) and 3.2 (brain metastasis from small cell lung carcinoma) at 18-24 h post injection. These preliminary data suggest that the use of gamma-emitter labelled 2-nitroimidazoles as diagnostic radiopharmaceuticals is feasible and safe, and that metabolic binding of 123I-IAZA is observed in some, but not all tumours. The inference that tumour 123I-IAZA avidity could be a non-invasive measure of tumour hypoxia deserves independent confirmation with needle oximetry.

Full text

PDF
90

Images in this article

92p92-a
on p.92
93Figure 2
on p.93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bush R. S., Jenkin R. D., Allt W. E., Beale F. A., Bean H., Dembo A. J., Pringle J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PMC free article] [PubMed] [Google Scholar]
  2. Chapman J. D., Baer K., Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 1983 Apr;43(4):1523–1528. [PubMed] [Google Scholar]
  3. Chapman J. D., Franko A. J., Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981 Apr;43(4):546–550. doi: 10.1038/bjc.1981.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chapman J. D., Lee J., Meeker B. E. Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):911–917. doi: 10.1016/0360-3016(89)90886-9. [DOI] [PubMed] [Google Scholar]
  5. Cobb L. M., Nolan J., Butler S. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):347–351. doi: 10.1016/0360-3016(90)90099-6. [DOI] [PubMed] [Google Scholar]
  6. Franko A. J., Chapman J. D., Koch C. J. Binding of misonidazole to EMt6 and V79 spheroids. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):737–739. doi: 10.1016/0360-3016(82)90724-6. [DOI] [PubMed] [Google Scholar]
  7. Franko A. J. Misonidazole and other hypoxia markers: metabolism and applications. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1195–1202. doi: 10.1016/0360-3016(86)90257-9. [DOI] [PubMed] [Google Scholar]
  8. Garrecht B. M., Chapman J. D. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. Br J Radiol. 1983 Oct;56(670):745–753. doi: 10.1259/0007-1285-56-670-745. [DOI] [PubMed] [Google Scholar]
  9. Gatenby R. A., Coia L. R., Richter M. P., Katz H., Moldofsky P. J., Engstrom P., Brown D. Q., Brookland R., Broder G. J. Oxygen tension in human tumors: in vivo mapping using CT-guided probes. Radiology. 1985 Jul;156(1):211–214. doi: 10.1148/radiology.156.1.4001408. [DOI] [PubMed] [Google Scholar]
  10. Gatenby R. A., Kessler H. B., Rosenblum J. S., Coia L. R., Moldofsky P. J., Hartz W. H., Broder G. J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988 May;14(5):831–838. doi: 10.1016/0360-3016(88)90002-8. [DOI] [PubMed] [Google Scholar]
  11. Hammersley P. A., McCready V. R., Babich J. W., Coghlan G. 99mTc-HMPAO as a tumour blood flow agent. Eur J Nucl Med. 1987;13(2):90–94. doi: 10.1007/BF00256023. [DOI] [PubMed] [Google Scholar]
  12. Henk J. M., Smith C. W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet. 1977 Jul 16;2(8029):104–105. doi: 10.1016/s0140-6736(77)90117-9. [DOI] [PubMed] [Google Scholar]
  13. Jette D. C., Wiebe L. I., Flanagan R. J., Lee J., Chapman J. D. Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization. Radiat Res. 1986 Feb;105(2):169–179. [PubMed] [Google Scholar]
  14. Mannan R. H., Somayaji V. V., Lee J., Mercer J. R., Chapman J. D., Wiebe L. I. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med. 1991 Sep;32(9):1764–1770. [PubMed] [Google Scholar]
  15. Rasey J. S., Koh W. J., Grierson J. R., Grunbaum Z., Krohn K. A. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):985–991. doi: 10.1016/0360-3016(89)90146-6. [DOI] [PubMed] [Google Scholar]
  16. Rauth A. M. Pharmacology and toxicology of sensitizers: mechanism studies. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1293–1300. doi: 10.1016/0360-3016(84)90335-3. [DOI] [PubMed] [Google Scholar]
  17. Rowell N. P., McCready V. R., Tait D., Flower M. A., Cronin B., Adams G. E., Horwich A. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br J Cancer. 1989 Jan;59(1):135–141. doi: 10.1038/bjc.1989.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Urtasun R. C., Koch C. J., Franko A. J., Raleigh J. A., Chapman J. D. A novel technique for measuring human tissue pO2 at the cellular level. Br J Cancer. 1986 Sep;54(3):453–457. doi: 10.1038/bjc.1986.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Urtasun R., Band P., Chapman J. D., Feldstein M. L., Mielke B., Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976 Jun 17;294(25):1364–1367. doi: 10.1056/NEJM197606172942503. [DOI] [PubMed] [Google Scholar]
  20. Varghese A. J., Whitmore G. F. Detection of a reactive metabolite of misonidazole in hypoxic mammalian cells. Radiat Res. 1984 Feb;97(2):262–271. [PubMed] [Google Scholar]
  21. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989 Dec 1;49(23):6449–6465. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES